CTIS2023-503465-33-00招募中1 期
ong-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis - 212358
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 292
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Male or female participants must be 18 to 80 years of age inclusive, at the time of signing the informed consent in the participant's parent study BAT117213, GLIMMER or GLISTEN Note: if country/site age requirements for consent differ, the more stringent (e.g., higher age) restriction will be required for that country/site., 2. Participants with a diagnosis of PBC and a history of associated pruritus as evidenced by randomization into a prior eligible linerixibat clinical study (BAT117213, GLIMMER or GLISTEN)., 3. Participants must have completed the main treatment period(s) in a prior eligible linerixibat clinical study (BAT117213, GLIMMER or GLISTEN)., 4. Contraceptive/Barrier Requirements (applicable for female participants only): A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: o Is a woman of non-childbearing potential (WONCBP) OR o Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method as described in Section 10.4 during the study intervention period (at a minimum until 4 weeks after the last dose of study intervention). The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated in relationship to the first dose of study intervention, etc.). -A WOCBP must have a negative highly sensitive urine pregnancy test (or serum, as required by local regulations) within 7 days before the first dose of study intervention, see Section 10.4 Pregnancy Testing. o If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive • Additional requirements for pregnancy testing during and after study intervention are listed in Section 8.2.5 Pregnancy Testing and Section 10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information. • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. Note: Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Full requirements for pregnancy testing during and after study intervention are located in Section 10.4 Appendix 4. Informed Consent., 5. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
排除标准
- •1. Screening total bilirubin >2x ULN. Note: Total bilirubin >2x ULN but <3x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%, 10. History of bariatric surgery with ileal bypass at any time, or any bariatric surgery performed in the past 3 years., 11. Any current medical condition (e.g. psychiatric disorder, senility, or dementia), which may affect the participant’s ability to comply with the protocol specified procedures., 12. Use of Obeticholic acid: within 8 weeks prior to the date of the Screening Visit and may not restart until after the End of Study or Early Study Withdrawal., 13. Administration of any other IBAT inhibitor in the 1 month prior to screening until after the End of Study or Early Study Withdrawal., 14. Current enro-llment or participation in any other clinical study (except for GLISTEN) involving an investigational study treatment within 8 weeks prior to the Screening Visit. Note: For participants coming from the GLISTEN study there is no specified waiting period before enrollment into this safety study., 15. QTc >480 msec at screening (12-lead ECG). Note: The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Frederica’s formula (QTcF), and/or another method. It is either machine-read or manually over-read, 16. Participants with moderate (or greater) alcohol consumption defined as more than one standard drink per day for women and two drinks per day for men; whereby one standard drink is equivalent to: 12 oz beer (5% alcohol), 5 ounces of wine (12% alcohol), or 1.5 ounces of 80 proof spirits (40% alcohol)., 2. Screening ALT or aspartate aminotransferase (AST) >6x ULN, 3. Screening estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m² based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. , 4. Group 2 Participants who meet increased liver chemistry monitoring criteria or any stopping criteria during LLSAT Screening period (GLISTEN Week 28 to Week 32 visit) or temporarily discontinue study treatment due to a drug-related adverse event during the LLSAT Screening period, which did not resolve prior to the time of the LLSAT Baseline Visit. Note: participants that meet increased liver chemistry monitoring criteria or stopping criteria at any timepoint during GLISTEN and restart of study intervention has not been approved by GSK are excluded., 5. Presence of hepatic decompensation (e.g., variceal bleeding, encephalopathy, or ascites)., 6. Presence of viral hepatitis B (HBsAg positive) or hepatitis C (anti-HCV positive and RNA detected) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease and/or confirmed hepatocellular carcinoma or biliary cancer., 7. Current clinically significant diarrhea in the investigator’s medical opinion. Polish, 8. Current symptomatic cholelithiasis or cholecystitis. Participants with history of cholecystectomy =3 months before screening may be eligible for enrollment. , 9. Any current malignancies (including hematologic and solid malignancies).
研究者
相似试验
进行中（未招募）
1 期
inerixibat Long-term Safety and Tolerability Study (LLSAT)Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 21.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-PLGlaxoSmithKline Research & Development Ltd75
进行中（未招募）
1 期
inerixibat Long-term Safety and Tolerability StudyModerate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 21.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-GBGlaxoSmithKline Research & Development Ltd75
进行中（未招募）
1 期
inerixibat Long-term Safety and Tolerability StudyModerate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 21.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-003158-10-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT75
进行中（未招募）
1 期
inerixibat Long-term Safety and Tolerability Study (LLSAT)Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 24.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-GRGlaxoSmithKline Research & Development Ltd295
招募中
3 期
inerixibat Long-term Safety, and Tolerability StudyJPRN-jRCT2080225120GlaxoSmithKline K.K.305